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Introduction
============

Chemotaxis is the mechanism that ensures guided relocalization of cells from one site to another and is pivotal within a plethora of biological and pathological processes ([@bib25]; [@bib17]; [@bib2]; [@bib6]; [@bib34]), including the dissemination of tumor cells in malignant disease ([@bib20]; [@bib21]). For such polarized motility, cell surface receptors must sense directional signals in the external environment and activate the intracellular chemosensory machinery. If the necessary polarity cues are absent or not activated, a cell can only migrate in random directions.

Urokinase-type plasminogen activator (uPA) and its receptor uPAR are strongly linked to cancer cell chemotaxis during invasion and metastasis ([@bib24]; [@bib27]; [@bib19]) and in this scenario uPAR has multiple functions. In particular, uPAR can focus and regulate the proteolytic activity of uPA at the plasma membrane. More intriguingly, uPAR acts as a central cell surface coordinator that transmits migratory and polarity cues into the cell. Because uPAR is a GPI-anchored receptor, its association with transmembrane coreceptors is required for this latter function as well as for the internalization of uPA--uPAR ([@bib5]). Endo180 was recently identified in chemical cross-linking studies as part of a trimolecular cell surface complex with uPA and uPAR ([@bib3]). This 180-kD transmembrane glycoprotein is one of the four members of the mannose receptor family ([@bib8]) and in common with other family members is a constitutively recycling endocytic receptor ([@bib14]; [@bib13]). Commensurate with its role as a uPAR coreceptor, Endo180 expression in normal tissue is restricted to stromal cells, macrophages, a subset of endothelial cells, and sites of chondrogenic/osteogenic activity with a marked increase in expression in tumor endothelium and breast cancer tissue ([@bib4]; [@bib8]; [@bib30]). Here, we directly addressed the question as to whether Endo180 can regulate uPA--uPAR mediated cell chemotaxis.

Results and discussion
======================

For initial studies, the MDA-MB-231 breast cancer cells were used as they express Endo180, uPAR and EGF receptor, and respond chemotactically to uPA and EGF ([@bib33]). The staining of Endo180 in MDA-MB-231 cells ([Fig. 1](#fig1){ref-type="fig"}) is consistent with previous reports that 10--30% of this receptor is in clathrin-coated pits at the cell surface, whereas 70--90% is located in endosomal compartments ([@bib14]; [@bib13]). uPAR is also detected in a clustered distribution, although it has a limited overlap with Endo180. Upon uPA stimulation, which is known to promote uPA--uPAR-Endo180 complex formation ([@bib3]), Endo180 and uPAR are translocated to the leading edge of polarized cells where they display a substantial degree of colocalization ([Fig. 1](#fig1){ref-type="fig"}). To directly investigate the role of Endo180 in these cells, a small interfering RNA (siRNA) approach was taken. Endo180 siRNA treatment resulted in a marked reduction in Endo180 expression ([Fig. 2](#fig2){ref-type="fig"} A; see [Fig. 4](#fig4){ref-type="fig"} C) but did not alter uPAR levels ([Fig. 2](#fig2){ref-type="fig"} A), indicating that expression of these two receptors is not coordinately regulated at the cell surface. This down-regulation of Endo180 had no effect on the basal migratory speed of unstimulated cells but significantly (P \< 0.001) reduced the motility of cells in response to uPA or EGF, or when cultured in the presence of a growth factor cocktail ([Fig. 2](#fig2){ref-type="fig"} B). This suggests a general role for Endo180 in the motility of cells stimulated by pro-migratory factors. The most striking alteration in the behavior of Endo180 siRNA treated cells was in their differential ability to respond directionally in chemotactic gradients of uPA and EGF. As expected from previous studies ([@bib33]), untreated (not depicted) or control siRNA treated MDA-MB-231 cells migrated directionally up gradients of uPA ([Fig. 2](#fig2){ref-type="fig"} C; Video 1, available at <http://www.jcb.org/cgi/content/full/jcb.200302124/DC1>) and EGF ([Fig. 2](#fig2){ref-type="fig"} C). Endo180 siRNA treatment significantly inhibited the chemotactic response to uPA ([Fig. 2](#fig2){ref-type="fig"} C; Video 2, available at <http://www.jcb.org/cgi/content/full/jcb.200302124/DC1>) but had no impact on the chemotactic response to EGF ([Fig. 2](#fig2){ref-type="fig"} C). To further investigate the structural interplay of Endo180 in the uPA--uPAR specific response, chemotaxis assays were performed in the presence of Endo180 mAbs E1/183 and A5/158. The four members of the mannose receptor family have a common structural organization of an NH~2~-terminal cysteine-rich domain, a fibronectin type II domain (FNII) and 8 or 10 C-type lectin-like domains (CTLDs), and single-particle electron microscopy has revealed that in Endo180 the NH~2~-terminal domains form a hairpin structure such that the cysteine-rich domain contacts CTLD2 ([@bib28]). mAb A5/158 binds to CTLD2 and totally blocks directional migration up a uPA gradient, whereas mAb E1/183, which binds the cysteine-rich domain, partially blocks uPA-induced chemotaxis ([Fig. 2](#fig2){ref-type="fig"} C; Fig. S1, see supplemental methods for a full definition of total and partial blockade, and available at <http://www.jcb.org/cgi/content/full/jcb.200302124/DC1>). The isotype matched mAb B3/25, which recognizes the endocytic transferrin receptor, had no effect on this response ([Fig. 2](#fig2){ref-type="fig"} C). Together, these findings indicate that a specific biological function of Endo180 is to regulate uPA--uPAR mediated directionality and suggest that accessibility of CTLD2 is required for a full biological response.

![**Endogenous Endo180 and uPAR colocalize in response to uPA stimulation.** MDA-MB-231 cells were stimulated with or without uPA for 30 min, fixed, permeabilized, and stained. Notably the colocalization of uPAR and Endo180 rich clusters in uPA-stimulated cells occurs in areas of new actin polymerization and membrane ruffling (as determined by costaining of uPAR or Endo180 with phalloidin; not depicted). Bar, 20 μm. Asterisk indicates area of interest magnified five times and shown in inset.](200302124f1){#fig1}

![**Endo180 is a general requirement for growth factor--stimulated cell motility but a specific promoter of directionality up a uPA gradient.** MDA-MB-231 cells were incubated with control or Endo180 siRNA oligonucleotides or left untreated and analyzed after 48 h. (A) FACS^®^ analysis of Endo180 and uPAR expression levels in control (green) and Endo180 (red) siRNA treated cells. Black lines show binding of second antibody alone to control siRNA treated cells. Endo180 expression in control siRNA treated cells was identical to that in untreated cells (not depicted). (B) Mean migratory speed of unstimulated, uPA- or EGF-stimulated cells, or cells cultured in growth factor cocktail (Opti-MEM medium). ct, control siRNA; E, Endo180 siRNA. Migratory speed values are given as the mean speed for all cells analyzed over the 5-h period ± SEM. (C) Chemotactic response of siRNA or mAb treated cells to a gradient of uPA or EGF. (B and C) Data shown includes analysis of \>50 cells pooled from at least three separate experiments. (C) Cell directionality was determined using the Rayleigh test and a horizon distance, which included 50% of all cells assayed for each treatment group. Analysis of the same data using 85% of cells is included in Fig. S1. This highly stringent approach discounts any bias in the calculation of directionality that might be caused by alterations in cell speed. Mean direction of cell migration (red arrow)/95% confidence interval (green wedge). (D) Epitope mapping of anti-Endo180 mAbs. Endo180-Fc constructs were resolved by 10% nonreducing SDS-PAGE and subject to Western blotting. The schematic diagram of Endo180 indicates mAb E1/183 binding to the cysteine-rich domain (CR) and mAb A51/58 binding to CTLD2.](200302124f2){#fig2}

To confirm that these effects of Endo180 were not cell type specific or an artifact of the siRNA system, stable populations of the uPAR and EGF receptor positive/Endo180 negative MCF-7 breast cancer cell line transfected with vector alone or Endo180 were generated ([Fig. 3](#fig3){ref-type="fig"} A). In agreement with the data obtained with MDA-MB-231 cells ([Fig. 2](#fig2){ref-type="fig"} B), Endo180 expression promoted a statistically significant (P \< 0.0001) twofold increase in random migration compared with vector-alone transfected cells ([Fig. 3](#fig3){ref-type="fig"} B). Although unstimulated parental or vector-alone transfected MCF-7 cells produced small membrane protrusions, they did not translocate on a Matrigel surface (Video 3, available at <http://www.jcb.org/cgi/content/full/jcb.200302124/DC1>) or a variety of other substrata including fibronectin, collagens I and IV. In contrast, MCF-7 cells expressing Endo180 exhibited increased membrane protrusion formation and translocated randomly on Matrigel (Video 4, available at <http://www.jcb.org/cgi/content/full/jcb.200302124/DC1>) and the other substrata tested. These observations indicate that Endo180 is both necessary and sufficient to evoke motility in this cell type. Parental or vector-alone transfected MCF-7 cells placed in a gradient of uPA displayed increased but nondirectional migration ([Fig. 3, B and C](#fig3){ref-type="fig"}; Video 5, available at <http://www.jcb.org/cgi/content/full/jcb.200302124/DC1>). The inability of vector-alone cells to detect a chemotactic gradient was consistent at 1, 5, 10, 15, 20, and 25 nM uPA, a concentration range within which the directional migration of MDA-MB-231 cells is maximally stimulated ([@bib33]). In accordance with the MDA-MB-231 cell data, MCF-7 cells expressing Endo180 were endowed with a sense of direction up a uPA gradient ([Fig. 3](#fig3){ref-type="fig"} C; Video 6, available at <http://www.jcb.org/cgi/content/full/jcb.200302124/DC1>; P \< 0.0001). Furthermore, this directional migration was totally inhibited by the anti-Endo180 mAb A5/158 ([Fig. 3](#fig3){ref-type="fig"} C) and was not associated with altered cell surface levels of uPAR ([Fig. 3](#fig3){ref-type="fig"} A). Conversely, both vector-alone cells and cells expressing Endo180 displayed increased migratory speed ([Fig. 3](#fig3){ref-type="fig"} B) and directionality up an EGF gradient that was unaffected by Endo180 mAbs ([Fig. 3](#fig3){ref-type="fig"} D), further confirming that directional sensing of an EGF gradient is an Endo180-independent process.

![**Expression of Endo180 is sufficient to confer a sense of direction up a concentration gradient of uPA.** (A) FACS analysis of Endo180 and uPAR cell surface expression levels in MCF-7 cells transfected with vector alone (green), wild-type Endo180 (red), or Endo180(Ala^1468^/Ala^1469^) (blue). Profiles in black represent vector transfected cells incubated with secondary antibody alone. (B) Mean migratory speed of transfected MCF-7. The directional data are summarized in a circular histogram showing the number of cells lying within each 18° interval. The mean direction and its 95% confidence interval are represented as a red arrow and green sector, respectively. (C, D) Chemotactic response of untreated or mAb A5/158-treated transfected MCF-7 cells in a gradient of uPA or EGF. Data shown in B--D includes analysis of \>70 cells pooled from at least three experiments. Cell directionality was determined using the Rayleigh test and a horizon distance which included 50% of all cells assayed for each treatment group. (C and D) The directional data are summarized in a circular histogram showing the number of cells lying within each 18 degree interval. The mean direction and its 95% confidence interval are represented as a red arrow and green sector, respectively.](200302124f3){#fig3}

Next, we addressed the mechanism by which Endo180 modulated migratory and chemotactic responses by examining MCF-7 cells transfected with an Endo180(Ala^1468^/Ala^1469^) construct. This mutant is expressed at the cell surface ([Fig. 3](#fig3){ref-type="fig"} A) but is internalization defective ([@bib13]; [@bib35]). In contrast to wild-type Endo180, expression of Endo180(Ala^1468^/Ala^1469^) did not increase the migratory speed of cells on Matrigel ([Fig. 3](#fig3){ref-type="fig"} B) or other substrata (not depicted), indicating that the random motility evoked by Endo180 is dependent on constitutive recycling of the receptor. Despite an impaired migratory speed ([Fig. 3](#fig3){ref-type="fig"} B), cells expressing Endo180(Ala^1468^/Ala^1469^) still displayed strong directional sensing of a uPA gradient (P \< 0.0001) and this directionality was totally blocked by mAb A5/158 ([Fig. 3](#fig3){ref-type="fig"} C). Similar to cells expressing wild-type Endo180, there was little effect of Endo180(Ala^1468^/Ala^1469^) expression on their migratory speed ([Fig. 3](#fig3){ref-type="fig"} B) or directionality ([Fig. 3](#fig3){ref-type="fig"} D) up a gradient of EGF or on the cell surface expression of uPAR ([Fig. 3](#fig3){ref-type="fig"} A). These results suggest that the ability of Endo180 to coordinate the directionality of a cell toward uPA can be transduced from its localization on the plasma membrane and is separate from its endocytic function.

The intracellular mechanisms for generation of polarity and migration in eukaryotic cells are beginning to be elucidated. Phospholipid and small Rho GTPase signaling pathways converge to regulate recruitment of Arp2/3 complex by WASP/WAVE family scaffolding proteins, which rapidly rearrange the actin cytoskeleton to produce structures that change the polarity and orientation of a cell ([@bib12]; [@bib34]). Much less is understood about how extracellular signals are linked to this intracellular machinery. To further elucidate the mechanism of Endo180-dependent chemotaxis, the effect of altered Endo180 expression on the temporal activation of the Rho-family GTPases Cdc42, Rac and RhoA was examined. These molecular switches have fundamental roles in cell migration and chemotaxis ([@bib23]; [@bib1]; [@bib17]) and their deregulation is strongly implicated in metastasis ([@bib15]; [@bib29]). More importantly, Rac and Cdc42 can regulate cell motility downstream of uPAR ([@bib18]; [@bib33]). In Endo180, but not vector-alone, expressing MCF-7 cells uPA stimulation increased filopodia production ([Fig. 4](#fig4){ref-type="fig"} A) and caused rapid and sustained activation of Cdc42 ([Fig. 4](#fig4){ref-type="fig"} B). Consistent with these findings, uPA-stimulated activation of Cdc42 in MDA-MB-231 cells was blocked by Endo180 siRNA, but not control siRNA, treatment ([Fig. 4](#fig4){ref-type="fig"} C), whereas EGF-stimulated Cdc42 activation was unaffected by Endo180 siRNA treatment ([Fig. 4](#fig4){ref-type="fig"} C). Despite an impaired activation of Cdc42, vector alone expressing cells show a substantial activation of Rac in response to uPA, which together may account for their increased migration without directional sensing in a uPA gradient. Although these data also suggest that Rac activation is not dependent on Endo180, the rapidity of uPA-dependent Rac activation in Endo180 transfected cells points to a regulatory role for this receptor in stimulating Rac activity. Endo180(Ala^1468^/Ala^1469^) expression resulted in delayed Cdc42 activation, but the level of activation stimulated by uPA was similar to that seen in Endo180 expressing cells. In contrast, Rac activation was impaired in Endo180(Ala^1468^/Ala^1469^) expressing cells providing a molecular explanation for the ability of these cells to sense a uPA gradient without increasing their migratory speed. Based on these results, we propose that Endo180 plays an important regulatory role in coordinating the activation of the Cdc42 and Rac GTPases during uPA-induced chemotaxis. In agreement with a previous report ([@bib16]), RhoA was not significantly activated by uPA in either the MCF-7 cell lines or MDA-MB-231 cells (unpublished data). uPA--uPAR signaling has been shown to activate the MAPK pathway ([@bib22]) and Akt (protein kinase B; [@bib33]; [@bib7]). However, wild-type Endo180 or Endo180(Ala^1468^/Ala^1469^) expression did not alter the time course of uPA-mediated extracellular signal--regulated kinase 1/2 (ERK1/2) phosphorylation in MCF-7 cells or enhance Akt phosphorylation ([Fig. 5](#fig5){ref-type="fig"} A).

![**Endo180 promotes filopodia formation in response to uPA and promotes rapid uPA--uPAR mediated activation of Cdc42 and Rac.** (A) Endo180 transfected MCF-7 cells were stimulated with or without uPA for 5 min, fixed and immunostained with mAb A5/158 and counterstained with Alexa 555-phalloidin. Bar, 10 μm. Quantitative values shown graphically represent mean ± SEM number of filopodia per cell from a total of 50 randomly chosen cells in two independent experiments. (B) Cdc42 and Rac activation time courses in MCF-7 cells transfected with vector alone (green), Endo180 (red) or Endo180(Ala^1468^/Ala^1469^) (blue) and stimulated with uPA. Values represent the mean ± SEM percent change from levels of vector alone cells at zero time point (*n* = 4--6 experiments). Bottom panels show representative immunoblots. (C) Endo180 expression and Cdc42 activation in siRNA treated MDA-MB-231 cells stimulated with uPA or EGF for 5 min ct, control siRNA; E, Endo180 siRNA. Left panel shows representative blot, right panel shows a graphical representation of mean ± SD percent change from levels in control siRNA treated cells (*n* = 2 experiments).](200302124f4){#fig4}

![**Endo189 expression does not alter ERK1/2 and Akt phosphorylation or cell surface LRP.** (A) ERK1/2 and Akt phosphorylation in MCF-7 cells transfected with vector alone, Endo180 or Endo180(Ala^1468^/Ala^1469^) and stimulated with uPA. Blots show phosphorylated ERK1/2 and Akt together with total ERK1/2 and Akt as loading controls. (B) FACS^®^ analysis of LRP cell surface expression levels in MCF-7 cells transfected with vector alone (green), wild-type Endo180 (red) or Endo180(Ala^1468^/Ala^1469^) (blue). Profiles in black represent vector transfected cells incubated with secondary antibody alone.](200302124f5){#fig5}

Finally, we considered the possibility that the effect of Endo180 on uPA-mediated cell chemotaxis might, at least in part, result from this constitutively recycling transmembrane receptor modulating the cell surface levels of other uPAR associated proteins. However, Endo180 expression was shown to have no effect on plasma membrane expression of either integrins ([@bib35]) or low density lipoprotein receptor--related protein (LRP; [Fig. 5](#fig5){ref-type="fig"} B)--uPAR coreceptors, which have been previously demonstrated to promote cell signaling and migration in response to uPA stimulation.

The findings of this paper demonstrate that coexpression of Endo180 and uPAR promotes the guided migration of breast tumor cells. This significantly advances our understanding of how these receptors may participate in metastatic spread and tumor progression. The up-regulation of Endo180 expression in tumor endothelium ([@bib32]) indicates a potential role for this receptor in the regulation of tumor neoangiogenesis, a process that is hallmarked by endothelial cell chemotaxis and has a strong dependence on the interaction between uPA and uPAR ([@bib19]; [@bib26]). In addition to its interaction with uPA--uPAR, Endo180 functions as a Ca^2+^-dependent mannose binding C-type lectin ([@bib10]) and as a collagen binding/internalization receptor ([@bib3]; [@bib35]), and binding of these ligands is mediated by CTLD2 and FNII, respectively. Furthermore, the functional interplay between the different ligand binding activities of Endo180 predicted in a recent 3D structural model ([@bib28]), is evidenced by the finding that collagens block the association with uPAR ([@bib3]), and as shown here, an antibody directed against the sugar binding CTLD2 blocks cellular responses to uPA. What is apparent from the data presented here is that role of Endo180 in promoting random "nondirectional" cell migration ([Figs. 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}; [@bib9]; [@bib11]) is dependent on receptor internalization and thereby mechanistically distinct from the unique function of Endo180 as a cell surface coordinator for setting up the internal cellular compass in a gradient of uPA.

Materials and methods
=====================

Reagents and cells
------------------

Rabbit anti-Endo180 polyclonal antibody and anti-Endo180 mAbs A5/158 and E1/183 have been described previously ([@bib14]; [@bib31]). B3/25 antitransferrin receptor mAb was a gift from C. Hopkins (Imperial College, London, UK). Mouse anti--human uPAR antibody 3936, (America Diagnostica, Inc.), mouse anti--human-LRP (Serotec), mouse anti--human pan-ERK1/2 (Sigma-Aldrich), mouse anti--human phospho-ERK1/2, rabbit anti--human pan-PKB/AKT, and mouse anti--human phospho-AKT (Upstate Biotechnology). Alexa555 anti--rabbit Ig, Alexa488 anti--mouse Ig and Alexa555-phalloidin (Molecular Probes), and HRP anti--mouse Ig (Jackson ImmunoResearch Laboratories). Catalytically inactive uPA, as used previously ([@bib33]), was a gift from J. Hamelin (Institut National de la Santé et de la Recherche Medicale U461, France) and EGF (R&D Systems) were used at 10 nM and 15 ng/ml, respectively, in all assays. Extracellular domain Endo180 constructs truncated after the cysteine-rich domain, FNII, CTLD1, CTLD2, CTLD4, or CTLD8 fused in frame with the Fc portion of human Ig were generated and expressed in COS-1 cells as described previously ([@bib10]). MCF-7 transfectants and siRNA treatment of MDA-MB-231 cells has been described previously ([@bib35]; see Online supplemental material). MCF-7 cells were maintained in DME + 10% FCS unless otherwise stated. MDA-MB-231 cells were cultured in DME + 10% FCS and starved in DME + 0.1% FCS for 24 h before analysis.

Cdc42, Rac, RhoA, ERK1/2, and Akt activation assays
---------------------------------------------------

MCF-7 or MDA-MB-231 cells were grown to 50% confluence and starved for 24 h in DME before treatment. Cells were lysed in ice-cold lysis buffer plus protease and phosphatase inhibitors. Active Cdc42, Rac, and RhoA were measured using assay kits according to the manufacturer\'s instructions (Upstate Biotechnology). ERK1/2 and Akt phosphorylation were measured by immunoblot analysis with phospho-specific antibodies.

Chemotaxis/migration assay
--------------------------

Chemotaxis and migration were measured by direct observation and recording of cell behavior in stable concentration gradients of 10 nM uPA or 15 ng/ml EGF using the Dunn chemotaxis chamber as described previously ([@bib1]; [@bib33]). Full details are provided in Online supplemental material.

Online supplemental material
----------------------------

Materials and methods describing the Endo180 siRNA oligonucleotides and methods of transfections, a detailed account of how the Dunn chamber chemotaxis experiments were undertaken, and how the data is analyzed. Fig. S1 shows the same data as shown in [Fig. 2](#fig2){ref-type="fig"} C but using a lower stringency analysis. Videos 1--6 show examples of Dunn chamber experiments. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200302124/DC1>.

Supplemental Material
=====================
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